在获得丰厚收入和积极致癌药物结果引发重大机构购买后,Gilead Science激增。 Gilead Sciences surged after strong earnings and positive cancer drug results sparked major institutional buying.

在2026年1月,Gilead Science看到机构兴趣增加,因为Ruffer LLP将股权提高了304%,米拉资产公司在Q3收入丰厚和3阶段试验成功后,将股权提高了9.7%。 In January 2026, Gilead Sciences saw increased institutional interest as Ruffer LLP raised its stake by 304%, and Mirae Asset boosted its holding by 9.7%, amid strong Q3 earnings and positive Phase 3 trial results for its Trodelvy cancer therapy. 分析家提高了价格目标, 包括BMO的150美元的预测。 The stock surged on the news, with analysts raising price targets, including BMO’s $150 forecast. 尽管首席执行官丹尼尔·奥戴 (Daniel ODay) 进行了1560万美元的内部信息销售和其他高管股票减持,但该公司仍然保持"中等购买"的共识评级和135.36美元的平均价格目标. Despite a $15.6 million insider sale by CEO Daniel O’Day and other executive share reductions, the company maintains a “Moderate Buy” consensus rating and a $135.36 average price target. Gilead有1 733.35亿美元的市场上限,定于2月10日报告2025年全年结果。 Gilead, with a $173.35 billion market cap, is set to report full-year 2025 results on February 10.